Personalized add-on treatment after cervical cancer surgery
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests whether a tailored “extra” treatment after surgery—guided by a lab test called minimal residual disease (MRD)—can reduce the risk of cervical cancer coming back. It focuses on people with certain stages of cervical cancer who can follow the treatment plan and study follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have cervical cancer in FIGO stage IB2 to IIA2
- Your overall health is good enough for study participation (ECOG 0 to 2)
- You can understand the study and sign informed consent, and you’ll follow the schedule
- You must be willing to provide samples and medical information at the required time points
- You can’t have another active cancer at the same time (other than cervical cancer)
- You must be able to receive the study’s planned treatment and follow-up tests (like CT or other required scans), without major changes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the immunotherapy drug Zimberelimab to standard chemoradiation after surgery for locally advanced cervical cancer. It aims to see if this combination helps prevent the cancer from coming back.
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
This trial tests a drug called adebrelimab combined with standard chemotherapy and radiation for cervical cancer. It may be an option for people with stage IIB to IVA cervical cancer who have not had prior treatment.
This trial tests a combination of three types of cancer-fighting drugs—an immunotherapy (camrelizumab), a targeted therapy (famitinib), and chemotherapy—to treat cervical cancer that has returned or spread. The goal is to see if this combination works better than standard treatment.
This study tests whether adding the drug nimotuzumab to standard chemoradiotherapy (radiation plus chemo) and then continuing maintenance therapy works better for locally advanced cervical cancer (stages IB3 to IVA) than chemoradiotherapy alone.
This trial tests whether adding tislelizumab to standard chemotherapy and radiation works better as first treatment for stage IIIC2 cervical cancer. It aims to improve how well the cancer responds and controls the disease.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.